

L Number	Hits	Search Text	DB	Time stamp
2	97125	bone	USPAT; EPO; JPO; DERWENT	2002/01/15 09:14
3	8	resveratrol and bone	USPAT; EPO; JPO; DERWENT	2002/01/15 08:49
4	1	9966913.pn.	USPAT; EPO; JPO; DERWENT	2002/01/15 06:27
5	554	genistein	USPAT; EPO; JPO; DERWENT	2002/01/15 06:47
6	4	resveratrol and genistein	USPAT; EPO; JPO; DERWENT	2002/01/15 06:47
7	19375	ischem\$	USPAT; EPO; JPO; DERWENT	2002/01/15 07:14
8	9	ischem\$ and resveratrol	USPAT; EPO; JPO; DERWENT	2002/01/15 07:14
9	2	5747536.pn.	USPAT; EPO; JPO; DERWENT	2002/01/15 07:25
10	3	4346107.pn.	USPAT; EPO; JPO; DERWENT	2002/01/15 07:25
11	29429	hypertension	USPAT; EPO; JPO; DERWENT	2002/01/15 09:26
12	7	hypertension and resveratrol	USPAT; EPO; JPO; DERWENT	2002/01/15 07:26
13	4	3624162.pn.	USPAT; EPO; JPO; DERWENT	2002/01/15 08:30
14	8	3624162.URPN.	USPAT; EPO; JPO; DERWENT	2002/01/15 08:24
15	109	\$resveratrol	USPAT; EPO; JPO; DERWENT	2002/01/15 08:31
16	1	\$resveratrol not resveratrol	USPAT; EPO; JPO; DERWENT	2002/01/15 08:31
1	108	resveratrol	USPAT; EPO; JPO; DERWENT	2002/01/15 08:31
17	46	("424/766").CCLS.	USPAT; EPO; JPO; DERWENT	2002/01/15 09:07
18	179	("568/729").CCLS.	USPAT; EPO; JPO; DERWENT	2002/01/15 09:10
20	0	bone and ("568/729").CCLS.)	USPAT; EPO; JPO; DERWENT	2002/01/15 09:10
21	65	514/733.ccls.	USPAT; EPO; JPO; DERWENT	2002/01/15 09:15
22	10	\$resveratrol and 514/733.ccls.	USPAT; EPO; JPO; DERWENT	2002/01/15 09:15
23	5	5747536.URPN.	USPAT; EPO; JPO; DERWENT	2002/01/15 09:17
24	7	hypertension and \$resveratrol	USPAT; EPO; JPO; DERWENT	2002/01/15 09:26

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition
1	BRS	L2	97125	bone	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:14		
2	BRS	L3	8	11 and 12	USPAT ; EPO; JPO; DERWE NT	2002/01/15 08:49		
3	BRS	L4	1	9966913.pn.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 06:27		
4	BRS	L5	554	genistein	USPAT ; EPO; JPO; DERWE NT	2002/01/15 06:47		
5	BRS	L6	4	11 and 15	USPAT ; EPO; JPO; DERWE NT	2002/01/15 06:47		
6	BRS	L7	19375	ischem\$	USPAT ; EPO; JPO; DERWE NT	2002/01/15 07:14		
7	BRS	L8	9	17 and 11	USPAT ; EPO; JPO; DERWE NT	2002/01/15 07:14		
8	BRS	L9	2	5747536.pn.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 07:25		
9	BRS	L10	3	4346107.pn.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 07:25		
10	BRS	L11	29429	hypertension	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:26		

	Err ors
1	0
2	0
3	0
4	0
5	0
6	0
7	0
8	0
9	0
10	0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition
11	BRS	L12	7	l11 and l1	USPAT ; EPO; JPO; DERWE NT	2002/01/15 07:26		
12	BRS	L13	4	3624162.pn.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 08:30		
13	BRS	L14	8	3624162.URPN.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 08:24		
14	BRS	L15	109	\$resveratrol	USPAT ; EPO; JPO; DERWE NT	2002/01/15 08:31		
15	BRS	L16	1	l15 not l1	USPAT ; EPO; JPO; DERWE NT	2002/01/15 08:31		
16	BRS	L1	108	resveratrol	USPAT ; EPO; JPO; DERWE NT	2002/01/15 08:31		
17	IS&R	L17	46	("424/766").CCLS.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:07		
18	IS&R	L18	179	("568/729").CCLS.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:10		
19	BRS	L20	0	l2 and l18	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:10		
20	BRS	L21	65	514/733.ccls.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:15		

	Err ors
11	0
12	0
13	0
14	0
15	0
16	0
17	0
18	0
19	0
20	0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition
21	BRS	L22	10	115 and 121	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:15		
22	BRS	L23	5	5747536.URPN.	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:17		
23	BRS	L24	7	111 and 115	USPAT ; EPO; JPO; DERWE NT	2002/01/15 09:26		

	Err ors
21	0
22	0
23	0

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal623paz

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload
NEWS 8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS 9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS 10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS 11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS 13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17	Oct 22	Over 1 million reactions added to CASREACT
NEWS 18	Oct 22	DGENE GETSIM has been improved
NEWS 19	Oct 29	AAASD no longer available
NEWS 20	Nov 19	New Search Capabilities USPATFULL and USPAT2
NEWS 21	Nov 19	TOXCENTER(SM) - new toxicology file now available on STN
NEWS 22	Nov 29	COPPERLIT now available on STN
NEWS 23	Nov 29	DWPI revisions to NTIS and US Provisional Numbers
NEWS 24	Nov 30	Files VETU and VETB to have open access
NEWS 25	Dec 10	WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
NEWS 26	Dec 10	DGENE BLAST Homology Search
NEWS 27	Dec 17	WELDASEARCH now available on STN
NEWS 28	Dec 17	STANDARDS now available on STN
NEWS 29	Dec 17	New fields for DPCI
NEWS 30	Dec 19	CAS Roles modified
NEWS 31	Dec 19	1907-1946 data and page images added to CA and CAPLUS
NEWS EXPRESS	August 15	CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 06:50:30 ON 15 JAN 2002

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 06:50:44 ON 15 JAN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 13 JAN 2002 HIGHEST RN 382591-40-4

DICTIONARY FILE UPDATES: 13 JAN 2002 HIGHEST RN 382591-40-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e genistein/cn

E1 1 GENISTA SCOPARIA, EXT./CN
E2 1 GENISTA TINCTORIA, EXT./CN
E3 1 --> GENISTEIN/CN
E4 1 GENISTEIN .BETA.-CYCLODEXTRIN 1:1 COMPLEX/CN
E5 1 GENISTEIN 4',7-BIS(HEMISUCCINATE)/CN
E6 1 GENISTEIN 4',7-DI-.ALPHA.-L-RHAMNOSIDE/CN
E7 1 GENISTEIN 4',7-DI-.BETA.-D-GLUCOPYRANOSIDE/CN
E8 1 GENISTEIN
4',7-DI-O-(TRI-O-ACETYL-.ALPHA.-L-RHAMNOPYRANOSIDE
)/CN
E9 1 GENISTEIN
4',7-DI-O-(TRI-O-ACETYL-.BETA.-L-QUINOXYLPYRANOSID
E)/CN
E10 1 GENISTEIN 4',7-DI-O-.BETA.-D-GLUCOSIDE/CN
E11 1 GENISTEIN 4',7-DIGLUCOSIDE/CN
E12 1 GENISTEIN 4',7-DIOLEATE/CN

=> e3

L1 1 GENISTEIN/CN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 446-72-0 REGISTRY
CN 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)- (9CI) (CA
INDEX

NAME)

OTHER CA INDEX NAMES:

CN **Genistein (6CI)**

CN Isoflavone, 4',5,7-trihydroxy- (8CI)

OTHER NAMES:

CN 4',5,7-Trihydroxyisoflavone

CN 5,7,4'-Trihydroxyisoflavone

CN Baichanin A

CN C.I. 75610

CN Genisteol

CN Genisterin

CN NPI 031L

CN Prunetol

CN Sophoricol

FS 3D CONCORD

MF C15 H10 O5

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,
CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, CSNB, DDFU,


DRUGU,

EMBASE, HODOC*, IPA, MEDLINE, MRCK*, NAPRALERT, NIOSHTIC, PIRA, PROMT,
RTECS*, SPECINFO, TOXCENTER, TOXLIT, USPATFULL

(*File contains numerically searchable property data)

Other Sources: EINECS**, NDSL**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2358 REFERENCES IN FILE CA (1967 TO DATE)

48 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2370 REFERENCES IN FILE CAPLUS (1967 TO DATE)

34 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file CAPLUS

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

5.90

TOTAL

SESSION

6.05

FILE 'CAPLUS' ENTERED AT 06:51:25 ON 15 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 15 Jan 2002 VOL 136 ISS 3
FILE LAST UPDATED: 14 Jan 2002 (20020114/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Caplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> file reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
0.34	6.39

FILE 'REGISTRY' ENTERED AT 06:51:44 ON 15 JAN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 13 JAN 2002 HIGHEST RN 382591-40-4
DICTIONARY FILE UPDATES: 13 JAN 2002 HIGHEST RN 382591-40-4

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e resveratrol/cn

```
E1          1      RESUSCITATION-PROMOTING FACTOR PROTEIN (MICROCOCCUS LUTEUS
S
                TRAIN JCM-3348)/CN
E2          1      RESUSCITATION-PROMOTING FACTOR PROTEIN (MICROCOCCUS LUTEUS
S
                TRAIN NCIMB-13267)/CN
E3          1 --> RESVERATROL/CN
E4          1      RESVERATROL .BETA.-D-GLUCOSIDE/CN
E5          1      RESVERATROL 12-C-.BETA.-GLUCOPYRANOSIDE/CN
E6          1      RESVERATROL 3-O-.BETA.-GLUCOPYRANOSIDE/CN
E7          1      RESVERATROL 4'-O-.BETA.-D-GLUCOPYRANOSIDE/CN
E8          1      RESVERATROL CIS-DEHYDRODIMER/CN
E9          1      RESVERATROL GLUCOSIDE/CN
E10         1      RESVERATROL SYNTHASE/CN
E11         1      RESVERATROL SYNTHASE (PEANUT)/CN
E12         1      RESVERATROL TRANS-DEHYDRODIMER/CN
```


=> e3

```
L2          1 RESVERATROL/CN
```

=> d 12

```
L2  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN  501-36-0  REGISTRY
CN  1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]- (9CI)  (CA INDEX
    NAME)
OTHER CA INDEX NAMES:
CN  1,3-Benzenediol, 5-[2-(4-hydroxyphenyl)ethenyl]-, (E)-
CN  3,4',5-Stilbenetriol (7CI, 8CI)
CN  Resveratrol (6CI)
OTHER NAMES:
CN  (E)-5-(p-Hydroxystyryl)resorcinol
CN  (E)-Resveratrol
CN  3,5,4'-Trihydroxystilbene
CN  CA 1201
CN  trans-Resveratrol
FS  STEREOSEARCH
DR  31100-06-8
MF  C14 H12 O3
CI  COM
LC  STN Files:  ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
    BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT,
    CEN, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IPA, MEDLINE,
    MRCK*, NAPRALERT, PHAR, PROMT, TOXCENTER, TOXLIT, USPATFULL
    (*File contains numerically searchable property data)
```

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

828 REFERENCES IN FILE CA (1967 TO DATE)
 38 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 835 REFERENCES IN FILE CAPLUS (1967 TO DATE)
 10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.90	12.29

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 06:52:26 ON 15 JAN 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 15 Jan 2002 VOL 136 ISS 3
 FILE LAST UPDATED: 14 Jan 2002 (20020114/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Caplus now provides online access to patents and literature covered in CA from 1907 to the present. Bibliographic information and abstracts were added in 2001 for over 3.8 million records from 1907-1966.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

The CA Lexicon is now available in the Controlled Term (/CT) field.

Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> 12

L3 832 L2

=> reveratrol

L4 5 REVERATROL

=> resveratrol

1048 RESVERATROL

8 RESVERATROLS

L5 1048 RESVERATROL
(RESVERATROL OR RESVERATROLS)

=> 13 or 15

L6 1081 L3 OR L5

=> bone

127571 BONE

14967 BONES

L7 132325 BONE
(BONE OR BONES)

=> 15(1)16

L8 1048 L5(L)L6

=> 17(1)16

L9 9 L7(L)L6

=> d 19 1-9 ti

L9 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Effect of polyphenols on calcium content and alkaline phosphatase activity
in rat femoral tissues in vitro

L9 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Inhibition of dioxin effects on **bone** formation in vitro by a newly described aryl hydrocarbon receptor antagonist, **resveratrol**

L9 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Phytoestrogen, resveratrol and women's health

L9 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Drugs, foods and oral compositions containing stilbene-type compounds

L9 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI Resveratrol composition useful to treat periodontal disease

L9 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS

TI **Resveratrol** attenuates ovariectomy-induced hypertension and **bone** loss in stroke-prone spontaneously hypertensive rats

L9 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS
 TI Resveratrol and red wine consumption

L9 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS
 TI Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells

L9 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS
 TI Is resveratrol an estrogen agonist in growing rats?

=> d 19 6-9 ti fbib abs

L9 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2002 ACS
 TI **Resveratrol** attenuates ovariectomy-induced hypertension and **bone** loss in stroke-prone spontaneously hypertensive rats
 AN 2000:364790 CAPLUS
 DN 133:99348
 TI **Resveratrol** attenuates ovariectomy-induced hypertension and **bone** loss in stroke-prone spontaneously hypertensive rats
 AU Mizutani, Kenichi; Ikeda, Katsumi; Kawai, Yasuhiro; Yamori, Yukio
 CS Life Science, Environmental Conservation and Development, Nutritional Medicine, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, 606-8501, Japan
 SO J. Nutr. Sci. Vitaminol. (2000), 46(2), 78-83
 CODEN: JNSVA5; ISSN: 0301-4800
 PB Center for Academic Publications Japan
 DT Journal
 LA English
 AB We examd. the effect of **resveratrol** (3,4',5-trihydroxy stilbene), a phenolic compd. found in the skins of most grapes, on blood pressure and **bone** loss in ovariectomized (OVX), stroke-prone spontaneously hypertensive rats (SHRSP). Nineteen-week-old female SHRSP were divided into a sham-ovariectomized (sham) group fed a control diet and two OVX groups fed either a control diet (OVX-Cont) or a diet supplemented with **resveratrol** (5 mg/kg per d: OVX-Resv). Ovariectomy induced significant increases in systolic blood pressure (SBP). **Resveratrol** lowered the SBP by 15% by the third week of administration, and this effect was maintained throughout the study. **Resveratrol** treatment also significantly enhanced endothelium-dependent vascular relaxation in response to acetylcholine (ACh) in OVX rats. Finally, femur breaking energies measured for the **resveratrol**-treated (OVX-Resv) group were significantly higher than those of the **resveratrol**-untreated (OVX-Cont) group. While no significant differences in calcium, magnesium and phosphorus content were found between the femurs of OVX-Cont and OVX-Resv rats, the femur hydroxy-proline-content in the OVX-Resv group was significantly higher than of the OVX-Cont group. We conclude that, in OVX-SHRSP, **resveratrol** acts by a similar mechanism to mammalian estrogens, lowering blood pressure by increasing dilatory responses to ACh. The present study also demonstrated that **resveratrol** was able to prevent ovariectomy-induced decreases in femoral **bone** strength.

RE.CNT 49

RE

- (3) Anderson, J; Proc Soc Exp Biol Med 1998, V217, P345 CAPLUS
- (4) Anthony, M; J Nutr 1996, V126, P43 CAPLUS
- (5) Arjmandi, B; J Nutr 1996, V126, P161 CAPLUS
- (7) Baysal, K; Clin Exp Pharmacol Physiol 1996, V23, P537 CAPLUS
- (8) Bolego, C; Life Sci 1997, V60, P2291 CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L9 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2002 ACS
 TI Resveratrol and red wine consumption
 AN 2000:4052 CAPLUS
 DN 132:333848
 TI Resveratrol and red wine consumption
 AU Slater, I.; Odum, J.; Ashby, J.
 CS Zeneca Central Toxicology Laboratory, Macclesfield, SK10 4TJ, UK
 SO Hum. Exp. Toxicol. (1999), 18(10), 625-626
 CODEN: HETOEA; ISSN: 0960-3271
 PB Stockton Press
 DT Journal
 LA English
 AB The effects of orally given **resveratrol** on 3 estrogen-sensitive targets (uterus, blood cholesterol, **bone** d.) were studied in ovariectomized rats. **Resveratrol** was given at 0.03 mg/kg/day (dose estd. from moderate red wine consumption in humans), 3, or 70 mg/kg/day in peanut oil for 14 days. Rats given 0.45 mg estradiol/kg/day s.c. served as pos. controls. The animals were sacrificed 24 h after the last doses. The uterus wt., **bone** mineral d. (BMD), and blood plasma HDL-cholesterol were detd. Estradiol increased the uterine wt., decreased HDL-cholesterol levels, and had no effect on BMD. **Resveratrol** had no effect on these 3 parameters. Thus, the estrogenic super-agonist activity obsd. earlier in MCF-7 cells in vitro is not predictive of the in vivo activity. It is unlikely, that the cardiovascular protective effects of red wine consumption are mediated via an estrogenic pathway.
- RE.CNT 5
 RE
 (1) Ashby, J; J Applied Toxicol 1999, V19, P39 CAPLUS
 (2) Ashby, J; Regul Toxicol Pharmacol 1997, V25, P226 CAPLUS
 (3) Dukes, M; J Endocrinol 1994, V141, P335 CAPLUS
 (4) Gehm, B; Proc Nat Acad Sci 1997, V94, P14138 CAPLUS
 (5) Turner, R; Endocrinology 1999, V140, P50 CAPLUS
- L9 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS
 TI Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells
 AN 1999:36541 CAPLUS
 DN 130:232445
 TI Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells
 AU Mizutani, Kenichi; Ikeda, Katsumi; Kawai, Yasuhiro; Yamori, Yukio
 CS Department of Environmental Preservation and Development, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, 6068501, Japan
 SO Biochem. Biophys. Res. Commun. (1998), 253(3), 859-863
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 AB Nutritional and pharmacol. factors are needed to prevent **bone** loss that occurs with increasing age. The chem. compds. that act on **bone** metab. as nutrients in food, however, are poorly understood. The effect of **resveratrol**, a natural phytoestrogen, on the proliferation and differentiation of osteoblastic MC3T3-E1 cells was

studied. **Resveratrol** dose-dependently increased DNA synthesis (10-9-10-7 M) of MC3T3-E1 cells. In addn., **resveratrol** increased alk. phosphatase (ALP) activity and prolyl hydroxylase activity of MC3T3-E1 cells (10-6-10-5 M). Moreover, the antiestrogen tamoxifen eliminated the stimulation of MC3T3-E1 cells (proliferation and ALP activity) by **resveratrol**. On the other hand, **resveratrol** inhibited prostaglandin E2 prodn. in MC3T3-E1 cells (10-8-10-6 M). Our present study is the first to demonstrate that **resveratrol** directly stimulates cell proliferation and differentiation of osteoblasts. (c) 1998 Academic Press.

RE.CNT 37

RE

- (2) Anderson, J; Proc Soc Exp Biol Med 1998, V217(3), P345 CAPLUS
 - (3) Benvenuti, S; J Bone Miner Res 1991, V6(9), P987 CAPLUS
 - (5) Chen, C; Gen Pharmacol 1996, V27, P363 CAPLUS
 - (6) Cheng, S; Calcif Tissue Int 1994, V55, P356 CAPLUS
 - (8) Feldman, D; Endocrinology 1997, V138, P1777 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS
 TI Is resveratrol an estrogen agonist in growing rats?
 AN 1999:11133 CAPLUS
 DN 130:177389
 TI Is resveratrol an estrogen agonist in growing rats?
 AU Turner, Russell T.; Evans, Glenda L.; Zhang, Minzhi; Maran, Avudaiappan; Sibonga, Jean D.
 CS Departments of Orthopedics, Biochemistry, and Molecular Biology, Mayo Graduate School of Medicine, Rochester, MN, 55905, USA
 SO Endocrinology (1999), 140(1), 50-54
 CODEN: ENDOAO; ISSN: 0013-7227
 PB Endocrine Society
 DT Journal
 LA English
 AB Trans-3,4,5-trihydroxystilbene (**resveratrol**), a polyphenolic compd. found in juice and wine from dark-skinned grape cultivars, was recently shown to bind to estrogen receptors in vitro, where it activated transcription of estrogen-responsive reporter genes. The purpose of this 6-day study in weanling rats was to det. the dose-response (1, 4, 10, 40, and 100 .mu.g/day) effects of orally administered **resveratrol** on estrogen target tissues. The solvent (10% ethanol) had no significant effect on any measurement or derived value. 17.beta.-Estradiol treatment (100 .mu.g/day) decreased the growth rate, final body wt., serum cholesterol, and radial **bone** growth (periosteal **bone** formation and mineral apposition rates) at the tibia-fibula synostosis. In the uterus, 17.beta.-estradiol treatment increased wet wt., epithelial cell height, and steady-state mRNA levels for insulin-like growth factor I. In contrast, **resveratrol** treatment had no significant effect on body wt., serum cholesterol, radial **bone** growth, epithelial cell height, or mRNA levels for insulin-like growth factor I. **Resveratrol** treatment resulted in slight increases in uterine wet wt. but significance was achieved at the 10-.mu.g dose only. A second expt. was performed to det. whether a high dose of **resveratrol** (1000 .mu.g/day) antagonizes the ability of estrogen to lower serum cholesterol. As was shown for the lower doses, **resveratrol** had no effect on body wt., uterine wet wt., uterine epithelial cell height, cortical **bone** histomorphometry, or serum cholesterol. 17.beta.-Estradiol significantly lowered serum cholesterol, and this response was antagonized by cotreatment with **resveratrol**. These in vivo results suggest, in contrast to prior in vitro studies, that

resveratrol has little or no estrogen agonism on reproductive and nonreproductive estrogen target tissues and may be an estrogen antagonist.

RE.CNT 25

RE

- (1) Bertelli, A; Int J Clin Pharmacol Res 1996, V16, P77 CAPLUS
 - (2) Bertelli, A; Int J Tissue React 1995, V17, P1 CAPLUS
 - (3) Bertelli, A; Int J Tissue React 1996, V18, P67 CAPLUS
 - (4) Black, L; J Clin Invest 1994, V93, P63 CAPLUS
 - (5) Cavolina, J; Endocrinology 1997, V138, P1567 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> save temp all bone/1

L# LIST L1-L9 HAS BEEN SAVED AS 'BONE/L'

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
19.61	31.90

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.48	-2.48

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 06:58:00 ON 15 JAN 2002